Eric Devroe
Equibles does not estimate personal net worth.
About Eric Devroe
Eric Devroe is recorded as COO at Acrivon Therapeutics, Inc. (ACRV). The newest filing on record that lists Eric Devroe as COO at Acrivon Therapeutics, Inc. (ACRV) is dated April 30, 2026. The proxy statement of Acrivon Therapeutics, Inc. reports total compensation of $1,358,003 for Eric Devroe in fiscal 2025, including a base salary of $528,745. Disclosed compensation is on record for 5 fiscal years. Acrivon Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Acrivon Therapeutics, Inc. includes Peter Blume-Jensen (CEO), Adam Levy (CFO), Adam Levy, Ph.D., M.B.A. (CFO) and 5 others.
Affiliation history
-
Current
Start not stated–present
Last confirmed April 30, 2026
Company network
Leadership on record at Acrivon Therapeutics, Inc.
- Peter Blume-Jensen CEO
- Adam Levy CFO
- Adam Levy, Ph.D., M.B.A. CFO
- Charles Baum, M.D., Ph.D. Board Member
- Ivana Magovcevic-Liebisch, Ph.D., J.D. Board Member
- Kristina Masson Board Member
- Michael Tomsicek, M.B.A. Board Member
- Santhosh Palani, Ph.D., CFA Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Acrivon Therapeutics, Inc. (ACRV) | Chief Operating Officer | $528,745 | $1,358,003 |
| 2024 | Acrivon Therapeutics, Inc. (ACRV) | Chief Operating Officer | $510,467 | $1,146,728 |
| 2023 | Acrivon Therapeutics, Inc. (ACRV) | Chief Operating Officer | — | — |
| 2022 | Acrivon Therapeutics, Inc. (ACRV) | Chief Operating Officer | $386,779 | $2,179,897 |
| 2021 | Acrivon Therapeutics, Inc. (ACRV) | Chief Operating Officer | $300,000 | $462,939 |
Recent activity
No call appearances or filed executive changes recorded yet.